EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China

Longfei Wu, Haiqing Song, Chi Zhang, Anxin Wang, Bowei Zhang, Chiyu Xiong, Xianbo Zhuang, Yingzhuo Zang, Chenghao Li, Qi Fang, Chuanqiang Qu, Lihua Wang und 9 weitere

JAMA Network Open · 20.06.2023 · 6 (6) · e2317574

DOI: 10.1001/jamanetworkopen.2023.17574 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 20.06.2023. Verfasst von Longfei Wu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Stroke, Brain Ischemia, Ischemic Stroke, Panax notoginseng. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Preclinical and clinical studies have suggested the neuroprotective effect of Panax notoginseng saponins (Xuesaitong soft capsules). However, robust evidence in patients with ischemic stroke is lacking.

Objective

To assess the efficacy and safety of Xuesaitong soft capsules in patients with ischemic stroke. Design, Setting, and Participants This multicenter, double-blind, placebo-controlled randomized clinical trial was conducted at 67 tertiary health centers in China from July 1, 2018, to June 30, 2020. Included patients were aged 18 to 75 years with a diagnosis of ischemic stroke and a National Institutes of Health Stroke Scale score between 4 and 15.

Interventions

Eligible patients were randomly assigned within 14 days after symptom onset to receive either treatment with Xuesaitong soft capsules (120 mg orally twice daily) or placebo (120 mg orally twice daily) for 3 months. Main Outcomes and Measures The primary outcome was functional independence at 3 months, defined as a modified Rankin Scale score of 0 to 2.

Results

Among 3072 eligible patients with ischemic stroke who were randomized, 2966 (96.5%) were included in the modified intention-to-treat cohort (median [IQR] age, 62 [55-68] years; 1982 male [66.8%]). The number of patients who achieved functional independence at 3 months was 1328 (89.3%) in the Xuesaitong group and 1218 (82.4%) in the control group (odds ratio, 1.95; 95% CI, 1.56-2.44; P < .001). In the safety cohort, serious adverse events occurred in 15 of 1488 patients (1.0%) in the Xuesaitong group and 16 of 1482 (1.1%) in the control group ( P = .85). Conclusions and Relevance In this randomized clinical trial, Xuesaitong soft capsules significantly increased the likelihood of functional independence at 3 months in patients with ischemic stroke, indicating that this may be a safe and effective alternative therapy to improve prognosis in this population. Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR1800016363

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrokeBrain IschemiaIschemic StrokePanax notoginsengSaponinsUnited StatesHumansAdultMaleMiddle AgedCapsulesTreatment Outcome

Substanzen

CapsulesSaponins

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Institute for Brain Disorders, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Neurology, Jiang'an County People's Hospital, Sichuan, China.
  • Department of Neurology, Liaocheng People's Hospital, Shandong, China.

Zitieren

APA

Wu, L., Song, H., Zhang, C., Wang, A., Zhang, B., Xiong, C., Zhuang, X., Zang, Y., Li, C., Fang, Q., Qu, C., Wang, L., Zhang, M., Li, H., Wang, X., Li, Y., Xia, L., Yao, Z., Nie, Z., …, & Ji, X. (2023). Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China. JAMA Network Open, 6(6), e2317574. https://doi.org/10.1001/jamanetworkopen.2023.17574

Vancouver

Wu L, Song H, Zhang C, Wang A, Zhang B, Xiong C, et al. Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China. JAMA Network Open. 2023;6(6):e2317574. doi:10.1001/jamanetworkopen.2023.17574

BibTeX
@article{Wu2023,
  author = {Wu, Longfei and Song, Haiqing and Zhang, Chi and Wang, Anxin and Zhang, Bowei and Xiong, Chiyu and Zhuang, Xianbo and Zang, Yingzhuo and Li, Chenghao and Fang, Qi and Qu, Chuanqiang and Wang, Lihua and Zhang, Mei and Li, Hao and Wang, Xiaoli and Li, Yanan and Xia, Lei and Yao, Zhigang and Nie, Zhi and Gao, Ying and Ji, Xunming},
  title = {Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {6},
  pages = {e2317574},
  doi = {10.1001/jamanetworkopen.2023.17574}
}
Kostenlos starten →